NEW YORK (GenomeWeb) – Human Longevity announced on Monday that it has completed a $220 million offering of Series B preferred stock.
The firm plans to use the proceeds to grow its business and expand its product offerings, including Health Nucleus, a comprehensive, genomic-enhanced, research-based health center; ongoing development of the HLI Knowledgebase which currently has more than 20,000 complete genomes coupled with phenotype data; the Comprehensive Cancer Program; and other sequencing programs.
Investors in this financing round include Illumina, Celgene, GE Ventures, and participants in the $80 million Series A round the firm closed in 2014.
"The closing of our Series B offering was completed with excellent results for HLI, despite especially challenging external financial markets," said Co-founder and CEO J. Craig Venter in a statement. "This is a tribute to the strength of our science, technology, and team. We continue to build our business, develop life-changing products, and hire world-class scientific, clinical, and technical leaders to help us meet our goal of revolutionizing healthcare."